Showing results (1901-1910 of 3,353) with videos related to
Sort By:
Pageof 336
Pharmacoeconomics|August 30, 2021
Why the Gap in Evaluating the Social Constructs and the Value of Medicines?Jacquelyn McRae, Eberechukwu OnukwughaPharmacoeconomics|June 15, 2015
Cost Effectiveness of Chemotherapeutic Agents and Targeted Biologics in Ovarian Cancer: A Systematic ReviewInsiya B Poonawalla, Rohan C Parikh, Xianglin L Du, et al.Pharmacoeconomics|May 7, 2015
Calculating the Baseline Incidence in Patients Without Risk Factors: A Strategy for Economic EvaluationScott D Nelson, Daniel Malone, Joanne LafleurPharmacoeconomics|May 7, 2015
The Effect of Obesity and Chronic Conditions on Medicare Spending, 1987-2011Lindsay Allen, Ken Thorpe, Peter JoskiPharmacoeconomics|July 28, 2016
Assessing the Value of Treatment to Address Various Symptoms Associated with Multiple Sclerosis: Results from a Contingent Valuation StudyPei-Jung Lin, Cayla J Saret, Peter J Neumann, et al.Pharmacoeconomics|July 21, 2016
Cost Effectiveness of IDegLira vs. Alternative Basal Insulin Intensification Therapies in Patients with Type 2 Diabetes Mellitus Uncontrolled on Basal Insulin in a UK SettingMelanie J Davies, Divina Glah, Barrie Chubb, et al.Pharmacoeconomics|April 22, 2020
Valuing the AD-5D Dementia Utility Instrument: An Estimation of a General Population TariffTracy A Comans, Kim-Huong Nguyen, Julie Ratcliffe, et al.Pharmacoeconomics|April 23, 2020
Health Economic Models for Metastatic Colorectal Cancer: A Methodological ReviewKoen Degeling, Martin Vu, Hendrik Koffijberg, et al.Pharmacoeconomics|August 12, 2016
Cost Effectiveness of Pneumococcal Vaccination in Children in Low- and Middle-Income Countries: A Systematic ReviewSurasak Saokaew, Ajaree Rayanakorn, David Bin-Chia Wu, et al.Pharmacoeconomics|August 23, 2025
Cost-Utility Analysis of Treatment Sequences for Moderate-to-Severe Crohn's DiseaseMatthijs M Versteegh, Simone A Huygens, Inigo Bermejo, et al.Pageof 336